Shares of Sun Pharma, a leading Indian pharmaceutical company, are in focus following President Donald Trump's announcement of 100% tariffs on imported branded pharmaceuticals unless companies agree to lower prices or manufacture within the United States. This executive order, enacted on April 2, poses significant challenges for pharmaceutical firms, particularly smaller and mid-sized companies that may not have existing agreements with the US government. Sun Pharma is identified as the Indian company most susceptible to these tariffs, as 20% of its revenue is derived from innovative medicines. According to global brokerage Jefferies, while generic drugs remain exempt, the maximum tariffs on Sun Pharma's innovative products, primarily produced in South Korea and the European Union, are likely to be capped at 15%. Following the announcement, Sun Pharma's share price fell nearly 2% to ₹1,694.65 on the Bombay Stock Exchange (BSE). Analysts suggest that the stock may experience a short-term reversal, with potential upward movement towards the ₹1,730–₹1,750 range if it maintains strength above ₹1,640.